A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.

[1]  E. Lee,et al.  Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  Lucila Ohno-Machado,et al.  Logistic regression and artificial neural network classification models: a methodology review , 2002, J. Biomed. Informatics.

[3]  Allan S. Detsky,et al.  Guidelines for Economic Analysis of Pharmaceutical Products , 1993, PharmacoEconomics.

[4]  V. Goel,et al.  Technology assessment and cost-effectiveness analysis: misguided guidelines? , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  A. Detsky,et al.  Ontario’s Formulary Committee , 2012, PharmacoEconomics.

[6]  Jinhyun Kim,et al.  Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance. , 2008, Health affairs.

[7]  Jung Goo Lee,et al.  Comparison between Logistic Regression and Artificial Neural Networks as MMPI Discriminator. , 2005 .